Douglas C.  Bryant net worth and biography

Douglas Bryant Biography and Net Worth

CEO of QuidelOrtho
Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

What is Douglas C. Bryant's net worth?

The estimated net worth of Douglas C. Bryant is at least $23.93 million as of February 22nd, 2021. Mr. Bryant owns 495,807 shares of QuidelOrtho stock worth more than $23,927,646 as of March 28th. This net worth estimate does not reflect any other investments that Mr. Bryant may own. Learn More about Douglas C. Bryant's net worth.

How do I contact Douglas C. Bryant?

The corporate mailing address for Mr. Bryant and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Douglas C. Bryant's contact information.

Has Douglas C. Bryant been buying or selling shares of QuidelOrtho?

Douglas C. Bryant has not been actively trading shares of QuidelOrtho during the last quarter. Most recently, on Monday, February 22nd, Douglas C. Bryant bought 5,000 shares of QuidelOrtho stock. The stock was acquired at an average cost of $165.30 per share, with a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 495,807 shares of the company's stock, valued at $81,956,897.10. Learn More on Douglas C. Bryant's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. The most recent insider tranaction occured on February, 23rd when CFO Joseph M Busky bought 2,150 shares worth more than $99,652.50. Insiders at QuidelOrtho own 2.7% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 2/23/2024.

Douglas C. Bryant Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2021Buy5,000$165.30$826,500.00495,807View SEC Filing Icon  
8/31/2020Buy5,000$174.99$874,950.00455,823View SEC Filing Icon  
8/11/2020Buy5,000$234.12$1,170,600.00450,823View SEC Filing Icon  
6/11/2020Buy5,000$160.33$801,650.00445,823View SEC Filing Icon  
8/30/2019Sell71,708$62.18$4,458,803.44326,692View SEC Filing Icon  
7/29/2019Sell21,789$57.78$1,258,968.42323,231View SEC Filing Icon  
6/28/2019Sell28,711$57.59$1,653,466.49View SEC Filing Icon  
6/26/2019Sell25,250$57.25$1,445,562.50307,280View SEC Filing Icon  
3/29/2019Sell25,250$65.64$1,657,410.00302,237View SEC Filing Icon  
3/27/2019Sell795$65.03$51,698.85302,237View SEC Filing Icon  
2/28/2019Sell22,153$65.62$1,453,679.86322,006View SEC Filing Icon  
2/26/2019Sell31,443$65.72$2,066,433.96322,006View SEC Filing Icon  
1/29/2019Sell25,250$55.09$1,391,022.50319,563View SEC Filing Icon  
11/28/2018Sell18,033$61.17$1,103,078.61303,058View SEC Filing Icon  
10/31/2018Sell7,217$65.10$469,826.70301,530View SEC Filing Icon  
9/28/2018Sell25,250$65.19$1,646,047.50319,563View SEC Filing Icon  
7/30/2018Sell12,000$65.84$790,080.00306,313View SEC Filing Icon  
7/27/2018Sell12,000$67.58$810,960.00306,313View SEC Filing Icon  
6/29/2018Sell36,000$66.05$2,377,800.00306,313View SEC Filing Icon  
6/27/2018Sell12,000$66.27$795,240.00306,313View SEC Filing Icon  
5/31/2018Sell36,000$62.08$2,234,880.00306,313View SEC Filing Icon  
5/29/2018Sell12,000$60.95$731,400.00306,313View SEC Filing Icon  
4/30/2018Sell36,000$56.09$2,019,240.00306,313View SEC Filing Icon  
4/27/2018Sell12,000$56.02$672,240.00306,313View SEC Filing Icon  
3/29/2018Sell36,000$51.63$1,858,680.00306,313View SEC Filing Icon  
3/27/2018Sell12,000$51.51$618,120.00306,313View SEC Filing Icon  
2/28/2018Sell36,000$44.32$1,595,520.00302,843View SEC Filing Icon  
2/26/2018Sell12,000$44.63$535,560.00302,843View SEC Filing Icon  
1/30/2018Sell12,000$46.82$561,840.00286,493View SEC Filing Icon  
12/29/2017Sell36,000$44.10$1,587,600.00286,493View SEC Filing Icon  
12/28/2017Sell12,000$44.12$529,440.00286,493View SEC Filing Icon  
12/27/2017Sell12,000$44.50$534,000.00286,493View SEC Filing Icon  
11/30/2017Sell36,000$37.36$1,344,960.00296,493View SEC Filing Icon  
11/28/2017Sell12,000$36.72$440,640.00296,493View SEC Filing Icon  
10/30/2017Sell12,000$41.15$493,800.00296,493View SEC Filing Icon  
10/27/2017Sell12,000$42.29$507,480.00296,493View SEC Filing Icon  
9/29/2017Sell36,000$42.91$1,544,760.00296,493View SEC Filing Icon  
9/28/2017Sell12,000$42.86$514,320.00296,493View SEC Filing Icon  
9/27/2017Sell12,000$42.17$506,040.00296,493View SEC Filing Icon  
8/31/2017Sell36,000$34.44$1,239,840.00296,493View SEC Filing Icon  
7/31/2017Sell36,000$33.83$1,217,880.00296,493View SEC Filing Icon  
6/30/2017Sell36,000$27.30$982,800.00296,493View SEC Filing Icon  
5/31/2017Sell36,000$24.98$899,280.00296,493View SEC Filing Icon  
5/30/2017Sell12,000$25.10$301,200.00296,493View SEC Filing Icon  
5/26/2017Sell12,000$24.90$298,800.00296,493View SEC Filing Icon  
4/28/2017Sell36,000$24.16$869,760.00296,493View SEC Filing Icon  
3/31/2017Sell37,080$22.50$834,300.00297,573View SEC Filing Icon  
2/28/2017Sell106,920$21.39$2,287,018.80View SEC Filing Icon  
11/30/2016Sell72,000$22.89$1,648,080.00298,011View SEC Filing Icon  
11/29/2016Sell24,000$22.84$548,160.00298,011View SEC Filing Icon  
11/28/2016Sell24,000$23.02$552,480.00298,011View SEC Filing Icon  
9/30/2016Sell69,168$21.76$1,505,095.68291,121View SEC Filing Icon  
8/30/2016Sell2,832$22.00$62,304.00276,843View SEC Filing Icon  
2/19/2016Buy3,700$13.91$51,467.00View SEC Filing Icon  
10/30/2015Buy20,000$19.76$395,200.00249,404View SEC Filing Icon  
7/24/2014Buy20,000$24.12$482,400.00View SEC Filing Icon  
See Full Table

Douglas C. Bryant Buying and Selling Activity at QuidelOrtho

This chart shows Douglas C Bryant's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $48.26
Low: $46.92
High: $48.44

50 Day Range

MA: $55.03
Low: $41.76
High: $72.25

2 Week Range

Now: $48.26
Low: $41.75
High: $98.67

Volume

703,274 shs

Average Volume

903,922 shs

Market Capitalization

$3.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11